A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Latest Information Update: 09 Apr 2025
At a glance
- Drugs Ponatinib (Primary)
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- Sponsors Otsuka Beijing Research Institute
- 30 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 11 Aug 2020 Status changed from not yet recruiting to recruiting.
- 29 May 2020 Planned initiation date changed from 30 Apr 2020 to 31 Jul 2020.